Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
Status:
Terminated
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and effectiveness of anakinra (Kineret) for treating
patients with neonatal-onset multisystem inflammatory disease (NOMID), also known as chronic
infantile neurological, cutaneous and arthropathy (CINCA) syndrome. This disease can cause
rash, joint deformities, brain inflammation, eye problems, and learning difficulties. Immune
suppressing medicines commonly used to treat other pediatric rheumatologic diseases do not
suppress NOMID symptoms and, if used long-term and in high doses, can cause harmful side
effects. Anakinra, approved by The Food and Drug Administration for treating rheumatoid
arthritis in adults, blocks a substance called IL-1 that may be an important factor in
causing the inflammation in NOMID.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)